基于"肠-肝轴"理论，微康益生菌开发了具有临床验证的益生菌菌株，例如核心菌株如凝结魏茨曼氏菌 BC99等，在临床试验中显著改善了肝功能指标（如ALT、AST、γ-GT等），并降低了内毒素水平，增 强了抗氧化能力。此外，复合菌株组合（如BLa80与LRa05）还在情绪健康方面表现出色，可缓解酒精 依赖和消化不良症状，提升整体生活质量。同时，微康益生菌依托AI驱动的菌株开发平台、完整的产 业链布局以及符合CNAS标准的检测中心，实现了从菌种筛选到产业化生产的全链服务。公司已与全球 多家临床机构合作，完成近百项临床试验，布局六大健康领域20余个研究方向，成为国内益生菌临床研 究与实践的领先力量。 随着"护肝"需求从医疗场景向日常保健延伸，以益生菌为代表的微生态干预手段，正逐步成为消费者践 行主动健康管理的重要选择。本次峰会不仅为行业提供了科学前沿的交流平台，也为"大护肝"成分矩阵 的构建与产品创新指明了方向。 11月20日，由中国保健协会市场工作委员会指导，国药励展及庶正康讯联合主办的2025中国营养健康秋 季市场峰会在南京国际博览中心成功举办。本届峰会以"解锁'大护肝'成分矩阵，挑战无声的健康杀 手"为主题，汇聚 ...

近年来，中国咖啡市场呈现出强劲增长态势与显著结构性变化，其中"功能性"正成为行业创新焦点。益 生菌凭借其健康多元特性，成为咖啡功能化发展的首选成分。。然而，益生菌与热饮结合面临关键挑战 ——多数益生菌不耐高温。，微康益生菌研发的凝结魏茨曼氏菌BC99作为 耐热型"不怕烫"孢子菌株， 可完美融入热咖啡，并确保菌株顺利抵达肠道，发挥调节肠道健康、护胃清幽等功效，从而保障消费者 充分体验益生菌咖啡的功能价值。 中国咖啡市场近年来呈现高速增长态势，新品牌快速崛起，同时健康化、功能化成为重要创新方向。根 据调研数据显示，中国咖啡市场规模从2016年的868.8亿元增长至2023年的1777.2亿元，预计2030年将达 3754.9亿元，年复合增长率约10.19%。瑞幸、库迪等本土品牌通过快速扩张占据主导，Manner、Seesaw 等新品牌快速崛起，消费人群90后为主力军：90后占咖啡消费人群的五成左右，人均年饮咖啡杯数从 2016年的9杯增至2023年的16.74杯，消费者年轻化，消费习惯逐渐日常化，展现巨大消费潜力。 随着疫情后，人们对健康的关注度增多，据Mordor Intelligence数据显示，2025年全 ...

Core Viewpoint - The 2025 Microbiome International Probiotic and Health Summit, co-hosted by Weikang Probiotics and the APC Microbiome Centre of Ireland, emphasizes the theme "Quality Bacteria, Quality Life," focusing on the forefront of probiotic research, evidence-based innovation, and sustainable development strategies in the industry [1][8]. Group 1: Keynote Addresses - Dr. Fang Shuguang, Chairman and Chief Scientist of Weikang Probiotics, and Paul Ross, a member of the American Academy of Microbiology and the Royal Irish Academy, delivered keynote addresses at the summit [5][9]. - The summit highlighted the transition of the global probiotic industry towards a science-based, quality-focused, and industrialized era, advocating for rigorous research design and traceable data for quality control [8][11]. Group 2: Research Reports - Renowned scholars, including Catherine Stanton from the Royal Irish Academy and experts from Fudan University and Suzhou University, presented reports on core topics such as cutting-edge probiotic research, scientific evidence, and future development [13]. - Catherine Stanton discussed the establishment of infant gut microbiota and its impact on host health, emphasizing the role of various factors in gut diversity and the clinical benefits of specific probiotics [14][16]. - Other presentations included innovative approaches to gut health management, the necessity of clinical evidence for probiotics, and the potential of probiotics in cancer treatment and chronic disease management [18][20][22][27]. Group 3: Industry Collaboration and Future Directions - The summit served as a vibrant platform for intellectual exchange, fostering meaningful collaborations and innovations in the probiotic field [11]. - Weikang Probiotics is committed to its mission of "Quality Bacteria, Quality Life," focusing on probiotic strain research, clinical evidence, and large-scale production to provide high-quality probiotic solutions for global consumers [27].